Journal articlePreclinical
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
EBioMedicine, 2025 Aug. Carvas AO, Leuthardt A, Kulka P and 9 others.
Study type
Journal article
Subjects
Animal / preclinical (no Humans MeSH term)
Journal
EBioMedicine
Published
2025 Aug
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AnimalsMiceMice, KnockoutBody WeightMaleBrainReceptor Activity-Modifying Protein 1Islet Amyloid PolypeptideReceptors, Islet Amyloid PolypeptideCalcitoninReceptor Activity-Modifying Protein 3Receptors, Calcitonin
Other papers on Cagrilintide
Randomized controlled trial · 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Randomized controlled trial · 2025Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page